206 articles with NovoCure Ltd.
Novocure Receives Reimbursement Approval for Optune in Japan for the Treatment of Newly Diagnosed Glioblastoma
Optune is a noninvasive, portable device approved in Japan to treat newly diagnosed and recurrent GBM.
Patients Who Used Optune More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure's EF-14 Trial
This is a median survival of 24.9 months from randomization and a five-year survival of 29.3 percent.
Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology
The 10 presentations include data on a new array layout that could allow delivery of TTFields to infra-tentorial brain tumors, and data showing correlation between TTFields intensity within and surrounding patients’ tumors and their clinical outcomes.
Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology
In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented.
Novocure Announces Six Clinical Presentations on Novocure's Phase III Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology
NovoCure announced today six clinical presentations on Novocure’s phase 3 pivotal EF-14 trial data in newly diagnosed glioblastoma (GBM) at the 22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16 through November 19, in San Francisco
Novocure today reported financial results for the three and nine months ended September 30, 2017, highlighting year-over-year and sequential growth in active patients and net revenues.
NovoCure Release: Combination Of Optune With Temozolomide Demonstrates Unprecedented Five-Year Survival For Newly Diagnosed Glioblastoma Patients
NovoCure Announces Data Presentations At The American Society For Radiation Oncology’s 2017 Annual Meeting
NovoCure Release: German Federal Joint Committee Announces Decision To Support A Clinical Trial To Study Optune For The Treatment Of Newly Diagnosed Glioblastoma
NovoCure Announces A Phase Ib Clinical Trial To Evaluate The Safety Of Marizomib And Temozolomide In Combination With Optune® As Adjuvant Therapy In Patients With Glioblastoma
NovoCure Data On Delivery Of Tumor Treating Fields To Be Presented At The 39th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society
NovoCure To Present Three Abstracts On Tumor Treating Fields And Pancreatic Cancer At The European Society For Medical Oncology 19th World Congress On Gastrointestinal Cancer
NovoCure Release: First Patient Enrolled In RTOG Trial Of Optune Together With Bevacizumab For Patients With Bevacizumab-Refractory Recurrent Glioblastoma